Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2013 · 1 min read
In brief
In brief
This case report describes successful treatment of a refractory segmental infantile hemangioma in a patient with PHACE syndrome using sirolimus after conventional therapies failed. The response to mTOR inhibition suggests a potential mechanistic role for mTOR signaling in hemangioma pathogenesis.
Written by the GCMD Library team from the article.
Statements in this article
Infantile hemangiomas are common benign tumors of childhood.
Infantile hemangiomas often regress satisfactorily without intervention.
A subset of infantile hemangiomas may lead to functional or cosmetic morbidity necessitating therapy.
PHACE syndrome is characterized by a variety of neurocutaneous and vascular anomalies that typically include segmental hemangiomas.
Treatment with sirolimus provided benefit with regression of the cutaneous infantile hemangioma in a patient with PHACE syndrome who failed conventional first-line therapies.
Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) pathway.